The stakes are high for cell and gene therapy manufacturers. The nature of these treatments, and their use of living human cells or genetic material, creates new intricacies and dependencies that disrupt the traditional commercialization process. The new commercialization process for these therapies is interconnected and personalized, requiring a higher degree of integration between specialized logistics, patient programs, and health outcomes evidence making data a strong connective thread that helps weave together the value story for these products.
Stakeholders, ranging from regulatory bodies to payers to prescribers and even to patients, will review the data generated during a cell or gene therapy clinical trial with more scrutiny than ever before. And, each stakeholder will have its own set of priorities and metrics by which it will judge the therapy. While this dynamic is not entirely new, the challenges for a manufacturer to provide this data and the consequences that may arise without it are. The decisions a manufacturer makes in clinical trial design and reporting will have greater implications for the commercial supply chain compared to traditional products.
To design a clinical trial that will deliver all of the data complexities ultimately required of a cell or gene therapy, a manufacturer must start with the end in mind - when the therapy is approved, covered, and available to patients. Trial designers must think about each stakeholder along the supply chain individually and collectively to understand the qualitative and quantitative measures each will need to appreciate the value of the therapy.
Ideally, the manufacturer should create a multi-disciplinary advisory group, made up of providers, payers, distributors and patients, which can offer guidance and perspective throughout the therapys life cycle. Their perspectives can be informed by early discussions with regulators agencies as well. For example, I have been on advisory boards where the preferred trial design for regulatory bodies differed substantially from the design preferred by healthcare decision makers. There will be times when stakeholder needs converge and diverge, so understanding their needs as early as possible in the development process will aid in the development of an effective data strategy to address the evidentiary gaps.
Two to three years pre-launch, manufacturers should go directly to relevant regulatory agencies to gain insight into their requirements and review the current marketplace to understand the data needed to support their therapy. Certainly, regulators are going to be interested in cure rate, failure rate, adverse events, and other anticipated data; however, they are also going to be particularly interested in the comparator that is selected for the study. More than 30 percent of cell and gene therapies target rare diseases associated with small and often widespread patient populations. Meaning, researchers will need to recruit patients from diverse geographic regions, and in each region, there could be a different established standard of care. Therefore, manufacturers will need to carefully consider and understand the treatment landscape in the geographies from which they pool patients to fill their trials.
Evaluating a commercialization partner
Fortunately, there is significant information available to help manufacturers educate themselves on these market nuances. Evaluating commercialization partners with expertise that ranges from a global to hyper-local understanding of care and requirements can help this process. Together, manufacturers and their partners can review the data, looking first for overlaps (e.g., evaluating which countries have the same standards of care and provide a comparator that is relevant to multiple regulatory bodies).
If, however, there is not significant overlap, a partner can help a manufacturer identify which country may be the best in which to launch its innovative product, providing it with an opportunity to obtain additional evidence for future markets. In addition, a partner can help identify what data is available from other clinical trials to possibly serve as an indirect comparator, allowing the manufacturer to benefit from not only its own data but also the research that has been done previously or is being done simultaneously.
As noted earlier, regulatory bodies arent the only stakeholders that need to be considered during the design of a cell or gene therapy clinical trial. Payers play a critical role in creating access to a manufacturers product. They, too, must be considered early in development at least prior to Phase III. Not only would it be devastating to patients eagerly awaiting the promise of a cell or gene therapy but also its extremely costly for a manufacturer to successfully navigate regulation, receive approval, and then not receive coverage for the therapy.
Much like the approach to regulators, manufacturers should invite payers to join in their processes. Its important to understand how insurers will view a particular therapy is this gene therapy likely a first line treatment or a third or fourth option? The trial data may show that the therapy had even higher efficacy rates in a sub-population within the cohort. This will influence how a payer interprets the value of the therapy and how it considers different coverage models.
Payers will look not only for the data relevant to regulators but also associated costs. For example, what is the cost of an adverse event while on a new therapy? And, how does that differ from the standard of care? It is important that a manufacturers data strategy capture resource utilization while on its therapy and the comparator or accepted standard of care to answer key questions. Are there hidden costs associated with the current standard of care that are eliminated by the new therapy? Does current practice create a side effect that must be managed and, therefore, has a cost to both the patient and the payer?
Of course, not all questions will be answered immediately. Commercial and private payers are also struggling to balance the burden of paying the upfront cost of the therapy with ensuring a long-term economic benefit to offset the initial investment. Significant research being done to better understand patient movement across healthcare plans and how that could potentially impact cell and gene therapy models moving forward. In the meantime, manufacturers must work with partners to understand payer concerns and to create the most compelling value story possible.
Beyond clinical trials
Once approvals and coverage are granted, manufacturers must contend with the level of uncertainty in real-world results, which is particularly high for cell and gene therapies. This uncertainty could strongly affect stakeholder confidence in cell and gene therapy use, which in turn, affects both the products success and ability to help patients. As we have seen with many specialty products in the past, approval does not always equate to adoption. Provider and patient education will be a large and critical component of any commercialization strategy for cell or gene therapies, and that education can be bolstered significantly by data. The right mix of data can help stakeholders gain confidence and mitigate concerns regarding efficacy as well as comparative effectiveness, adverse events and the impacts to the patient.
Therefore, the need for data does not end with the conclusion of a clinical trial. Cell and gene therapies have a level of interconnectivity between manufacturing, logistics, patient support, and reimbursement rarely seen in health care. As a result, cell and gene therapies will need in some ways like many other products constant, ongoing data collection, interpretation, and distribution. Manufacturers will need to build or more likely and more effectively enlist partners who can build integrated data sets that provide not only the therapy owner, but all stakeholders needle-to-needle visibility.
Go here to read the rest:
Data Strategy: The Connective Tissue Required to Bring Cell and Gene Therapies to Market - Drug Discovery & Development
- New gene therapy for sickle cell disease has been a long time coming, but is it a complete game-changer? - UCLA Health Connect - December 29th, 2023
- Sickle Cell Gene Therapy Reimbursement: Will Experience Matter? And Which Kind? - Pink Sheet - December 29th, 2023
- Cell and gene therapy will be top industry trend for pharma in 2024 - The Financial Express - December 29th, 2023
- Excision Bio Seeks to Suppress HIV Replication With CRISPR Gene Therapy - AJMC.com Managed Markets Network - December 29th, 2023
- Global Cell and Gene Therapy Manufacturing Industry is projected to surpass a valuation of US$ 240 B - PharmiWeb.com - December 29th, 2023
- Penn's gene therapy layoffs are the latest in biotech belt-tightening in Philly and beyond - The Philadelphia Inquirer - December 29th, 2023
- Adeno-associated Virus Gene Therapy Market is Projected to Grow at a CAGR of 43.4% from 2023-2033 - EIN News - December 29th, 2023
- How Does Gene Therapy Work? Types, Uses, Safety - Healthline - May 9th, 2023
- Gene therapy: Comprehensive overview and therapeutic applications - April 7th, 2023
- Thanks to collaboration between Stand Up Therapeutics and VectorBuilder, a paraplegic patient will get gene therapy for the first time - Business... - January 21st, 2023
- Gene editing | Definition, History, & CRISPR-Cas9 | Britannica - January 4th, 2023
- A short history of gene therapy - Boston Children's Answers - December 27th, 2022
- Gene Therapy Analytical Development Summit 2022 | Home - December 27th, 2022
- $3.5-Million Hemophilia Gene Therapy Is World's Most Expensive Drug - Scientific American - December 10th, 2022
- CAR T Global Consultant Inc. Announce their Collaboration with Titronbio - a company founded in Shanghai China by a renowned leader in the field of... - December 10th, 2022
- Cell and Gene Therapy Manufacturing Services Market Size In 2023 | Financial Performance, In-Depth Insight of Trends, Key Players (Thermo Fisher... - December 10th, 2022
- How Gene Therapy Can Cure or Treat Diseases | FDA - December 2nd, 2022
- FDA Approves First Gene Therapy to Treat Adults with Hemophilia B - FDA.gov - November 24th, 2022
- Fact Check-mRNA vaccines are distinct from gene therapy ... - Reuters - October 29th, 2022
- Gene therapy: The Potential for Treating Type 1 Diabetes - Healthline - October 13th, 2022
- The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia - PMLiVE - October 13th, 2022
- Gene Therapy Hits Its Stride in the Clinic - Genetic Engineering & Biotechnology News - October 13th, 2022
- FDA Expands Oversight of Cell and Gene Therapies - Pharmaceutical Technology Magazine - October 13th, 2022
- Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene... - October 13th, 2022
- Health Alert for Parents: How one boy is thriving following treatment with a gene therapy after receiving an early diagnosis - PR Newswire - October 13th, 2022
- M6P Therapeutics Presents Novel AAV Gene Therapy Approach for the Treatment of Gaucher Disease at the ESGCT 29th Annual Congress - Business Wire - October 13th, 2022
- Two Cell and Gene Therapies Manufactured at Lonza Houston Reach FDA Approval - Contract Pharma - October 13th, 2022
- Ascidian starts up with $50M and a twist on RNA editing - BioPharma Dive - October 13th, 2022
- Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Report 2022 - ResearchAndMarkets.com - Business Wire - October 13th, 2022
- Exopharm identifies two new lead programs as exosomes gain prominence in gene therapy - Stockhead - October 13th, 2022
- What Do We Know About Gene Therapy and Cystic Fibrosis? - The Epoch Times - October 13th, 2022
- CSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions for the cell and gene therapy market - PR Newswire APAC - PR... - October 13th, 2022
- Genomics in Cancer Care Market is estimated to be US$ 72.61 billion by 2032 with a CAGR of 16.3% during the forecast period 2032 - By PMI -... - October 13th, 2022
- After $100M deal, J&J links gene therapy to improved vision in early-phase trial - FierceBiotech - October 4th, 2022
- Bayer Head Admits COVID-19 Vaccine is Gene Therapy - October 4th, 2022
- New Gene Therapy Shows Promise for Treating Age Related Macular ... - October 4th, 2022
- BioMarin resubmits its hemophilia gene therapy to the FDA - BioPharma Dive - October 4th, 2022
- Why Philly ranks #2 among best cell and gene therapy hubs in the US - Technical.ly - October 4th, 2022
- AMPLIFYBIO ACQUIRES PACT PHARMA ASSETS TO ENHANCE CELL AND GENE THERAPY CHARACTERIZATION CAPABILITIES - PR Newswire - October 4th, 2022
- bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line - Zacks Investment Research - October 4th, 2022
- Researchers Develop Potential Gene Therapy to Treat Blindness - Managed Healthcare Executive - October 4th, 2022
- Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy - GlobeNewswire - October 4th, 2022
- Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market by Scale of Operation, Type of Vector, Application... - October 4th, 2022
- Sanofi partners with Scribe to gain gene editing tools for cell therapy work - BioPharma Dive - October 4th, 2022
- Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time... - October 4th, 2022
- Vertex given green light to seek US approval of CRISPR-based therapy - BioPharma Dive - October 4th, 2022
- Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital... - October 4th, 2022
- Meet with the OrganaBio executives in-person at The Cell & Gene Meeting on the Mesa - Business Wire - October 4th, 2022
- Ocular Gene Therapy: A Literature Review With Focus on Current Clinical Trials - Cureus - September 25th, 2022
- Will experience support use of first-ever retinal gene therapy? - Ophthalmology Times - September 25th, 2022
- Rejuvenate Bio CEO highlights ambitious approach of using gene therapy to reverse aging - MedCity News - September 25th, 2022
- Gene therapy R&D market is projected to grow at a CAGR of 30.1% by 2032: Visiongain Reports Ltd - GlobeNewswire - September 25th, 2022
- Emulate Announces New Gene Therapy Application Enabling Accelerated Development of Treatments for Genetic Diseases with Organ-on-a-Chip Technology -... - September 25th, 2022
- CSL flexes gene therapy muscle with latest drug - Sydney Morning Herald - September 25th, 2022
- FDA Updates for the Week of Sept. 19, 2022 - Managed Healthcare Executive - September 25th, 2022
- AVROBIO Receives Rare Pediatric Disease Designation From FDA For First Gene Therapy In Development For Cy - Benzinga - September 25th, 2022
- Preparing Europe for a new generation of innovative therapies - Open Access Government - September 25th, 2022
- KSQ Therapeutics Announces Leadership and Board Additions - Business Wire - September 25th, 2022
- Hemophilia gene therapies from BioMarin, CSL pick up an early ICER endorsement - FiercePharma - September 16th, 2022
- Challenges In Gene Therapy - University of Utah - September 16th, 2022
- Hopkinton bioscience company forms advisory board for cell and gene therapy - Worcester Business Journal - September 16th, 2022
- Gene Therapy Restores Some Vision in Colorblind Children - Pharmacy Times - September 16th, 2022
- Coave Therapeutics partners with IMN on gene therapy - Labiotech.eu - September 16th, 2022
- MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government -... - September 16th, 2022
- Bluebird CFO resigns ahead of gene therapy launch - BioPharma Dive - September 16th, 2022
- Enrollment completed in STARLIGHT Phase 2 clinical trial of MCO-010 optogenetic gene therapy for Stargardt disease - Ophthalmology Times - September 16th, 2022
- Global Cancer Gene Therapy Market to Reach $11.35 Billion by 2030 at a CAGR of 23.3% - PR Newswire - September 16th, 2022
- How WhiteLab Genomics is using AI to aid gene and cell therapy development - TechCrunch - September 16th, 2022
- CAR-T Cell Therapy Market Segmentation and Forecast Analysis up to 2027 - BioSpace - September 16th, 2022
- Cluster-busters against Cancer and a Potential New Gene Therapy for LCA - BioSpace - September 16th, 2022
- Ori Biotech and CTMC team up on cell therapy delivery - BioPharma-Reporter.com - September 16th, 2022
- Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study - Zacks Investment Research - September 16th, 2022
- Engensis Gene Therapy for ALS Found Safe in Small Phase 2a Trial |... - ALS News Today - September 8th, 2022
- A new gene therapy based on antibody cells is about to be tested in humans - MIT Technology Review - September 8th, 2022
- Myrtelles rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Advanced Therapy Medicinal Product Classification from the European... - September 8th, 2022
- Sangamo presses ahead with Fabry disease gene therapy - BioPharma Dive - September 8th, 2022
- The gene therapy that could transform the lives of millions - ABC News - September 8th, 2022
- As Philly becomes a hub for life sciences, a new program will train workers for jobs in the field - The Philadelphia Inquirer - September 8th, 2022
- Mayflower BioVentures to Announce New Cell & Gene Therapy Companies within Months - BioSpace - September 8th, 2022
- Carroucell Raises 1.5 Million to Introduce Breakthrough Microcarriers and Customizable Processes to Cell and Gene Therapy Market - Business Wire - September 8th, 2022